MGMT methylation assessed by the qMSP test has been consistently shown to predict response to the alkylating agent TMZ, measured by either PFS or overall survival, in GBM patients [13], [28], [29], [30], [31], [32]. This evidence concerns the gene MGMT and glioblastoma.